Dlbcl
An aggressive and rapidly growing cancer of the B-cells that presents with rapidly enlarging lymph nodes, but is potentially curable with intensive chemoimmunotherapy.
Emergency Management: Tumor Lysis Syndrome: Start aggressive IV hydration and Rasburicase 0.2 mg/kg IV immediately to break down uric acid and prevent acute renal failure.
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive (fast-growing) type of non-Hodgkin lymphoma (NHL) that originates from mature B-lymphocytes. It is characterized by the diffuse proliferation of large, atypical neoplastic B-cells that efface the normal lymph node architecture.
Detailed Overview
DLBCL is the most common subtype of NHL. It is highly heterogeneous, categorized clinically into germinal center B-cell (GCB) and activated B-cell (ABC) subtypes based on cell-of-origin. Without treatment, it is rapidly fatal. However, it is highly sensitive to chemoimmunotherapy, making it a potentially curable disease in over 60% of cases. Relapsed or refractory disease remains a major clinical challenge, driving the development of novel therapies like CAR-T cells.
Epidemiology & Demographics
Accounts for 30-40% of all NHL cases worldwide. Incidence increases with age; the median age at diagnosis is ~64 years. Slightly more common in men than in women. Incidence is ~7 per 100,000 per year in the US.
Etiological Mechanism
Most cases arise de novo, but some result from transformation of indolent lymphomas (e.g., follicular lymphoma, CLL/SLL—Richter transformation). Genetic alterations involving BCL2, BCL6, and MYC genes are central to its pathogenesis.
Primary Causes
Acquired genetic mutations in B-lymphocytes. Immune dysregulation and viral infections can also be causal.
DLBCL results from the malignant transformation of a B-cell, usually during its transit through the germinal center of a lymph node. Genetic translocations (e.g., t(14;18) involving BCL2, or t(8;14) involving MYC) lead to uncontrolled proliferation and evasion of apoptosis. The malignant large cells diffusely infiltrate lymph nodes, extranodal tissues (like the GI tract, CNS, bone marrow), and disrupt normal organ function.
Diagnostic Criteria & Guidelines
Requires an excisional lymph node biopsy. Histology shows diffuse effacement of nodal architecture by large atypical B-cells. Immunohistochemistry is positive for pan-B-cell markers (CD19, CD20, CD22, CD79a) and negative for T-cell markers. Ki-67 proliferation index is usually high (>40-80%).
R-CHOP chemoimmunotherapy regimen given every 21 days for 6 cycles. Regimen: Rituximab (375 mg/m2 IV), Cyclophosphamide (750 mg/m2 IV), Doxorubicin (Hydroxydaunorubicin) (50 mg/m2 IV), Vincristine (Oncovin) (1.4 mg/m2 IV, max 2 mg), and Prednisone (100 mg PO days 1-5). CNS prophylaxis (Intrathecal Methotrexate) may be added for high-risk patients.
Second-Line & Adjunctive Therapy
For relapsed/refractory disease: Salvage chemotherapy (e.g., R-ICE or R-DHAP) followed by High-Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT) for transplant-eligible patients. CD19-directed CAR-T cell therapy (e.g., Axicabtagene ciloleucel or Tisagenlecleucel) is highly effective for primary refractory or post-ASCT relapsed disease.
Surgical & Procedural Management
Rarely indicated, except for obtaining excisional biopsies or managing complications like bowel obstruction/perforation.
Patient Counseling & Advice
Inform the patient that DLBCL is aggressive but potentially curable. Discuss the high likelihood of chemotherapy-induced alopecia (hair loss), fatigue, and the critical need to report fevers >38°C immediately due to the risk of neutropenic sepsis.
Follow-Up & Monitoring Schedule
PET/CT midway through treatment (interim PET) and at the end of treatment. Clinical exams and routine labs (CBC, LDH) every 3-6 months for the first 2 years, as most relapses occur within this window.
Preventive Strategies
No specific prevention. Optimizing management of underlying immunosuppressive states (e.g., strict HIV control) reduces risk.
Curable in ~60-70% of patients. Prognosis is estimated using the International Prognostic Index (IPI) based on Age >60, elevated LDH, poor performance status, Ann Arbor stage III/IV, and >1 extranodal site. 5-year OS ranges from 90% (low risk) to 50% (high risk).